223 related articles for article (PubMed ID: 18838478)
1. Blocking the APRIL circuit enhances acute myeloid leukemia cell chemosensitivity.
Bonci D; Musumeci M; Coppola V; Addario A; Conticello C; Hahne M; Gulisano M; Grignani F; De Maria R
Haematologica; 2008 Dec; 93(12):1899-902. PubMed ID: 18838478
[TBL] [Abstract][Full Text] [Related]
2. Addition of PTK787/ZK 222584 can lower the dosage of amsacrine to achieve equal amounts of acute myeloid leukemia cell death.
Weidenaar AC; de Jonge HJ; Fidler V; ter Elst A; Meeuwsen-de Boer T; Douwes J; Bouma-ter Steege JC; Hählen K; Kamps WA; de Bont ES
Anticancer Drugs; 2008 Jan; 19(1):45-54. PubMed ID: 18043129
[TBL] [Abstract][Full Text] [Related]
3. Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia.
Haiat S; Billard C; Quiney C; Ajchenbaum-Cymbalista F; Kolb JP
Immunology; 2006 Jul; 118(3):281-92. PubMed ID: 16827889
[TBL] [Abstract][Full Text] [Related]
4. Effects of dexamethasone on Flt3 receptor expression and proliferation induced by recombinant human Flt3 ligand in malignant hematopoietic cells.
Xu ZX; Xu Y; Zhu JK; Li CX; Li Y; Zhang XG
Acta Pharmacol Sin; 2001 Jun; 22(6):534-40. PubMed ID: 11747761
[TBL] [Abstract][Full Text] [Related]
5. [Drug sensitivity of tumor cells in varieties of acute childhood leukemia].
Shman TV; Belevtsev MV; Buglova SE
Vopr Onkol; 2005; 51(5):558-62. PubMed ID: 16756010
[TBL] [Abstract][Full Text] [Related]
6. BAFF and APRIL expression in B-cell chronic lymphocytic leukemia: correlation with biological and clinical features.
Bojarska-Junak A; Hus I; Chocholska S; Wasik-Szczepanek E; Sieklucka M; Dmoszyńska A; Roliński J
Leuk Res; 2009 Oct; 33(10):1319-27. PubMed ID: 19395025
[TBL] [Abstract][Full Text] [Related]
7. Additive effect of PTK787/ZK 222584, a potent inhibitor of VEGFR phosphorylation, with Idarubicin in the treatment of acute myeloid leukemia.
Barbarroja N; Torres LA; Luque MJ; Carretero RM; Valverde-Estepa A; Lopez-Sanchez LM; Rodriguez-Ariza A; Velasco F; Torres A; López-Pedrera C
Exp Hematol; 2009 Jun; 37(6):679-91. PubMed ID: 19463770
[TBL] [Abstract][Full Text] [Related]
8. Reversal of drug resistance by silencing Survivin gene expression in acute myeloid leukemia cells.
Wu YH; You Y; Chen ZC; Zou P
Acta Biochim Pol; 2008; 55(4):673-80. PubMed ID: 19093040
[TBL] [Abstract][Full Text] [Related]
9. In vitro cross-resistance to nucleoside analogues and inhibitors of topoisomerase 1 and 2 in acute myeloid leukemia.
Fiegl M; Zimmermann I; Lorenz I; Hiddemann W; Braess J
Ann Hematol; 2008 Jan; 87(1):27-33. PubMed ID: 17710400
[TBL] [Abstract][Full Text] [Related]
10. Circumvention of glucocorticoid resistance in childhood leukemia.
Haarman EG; Kaspers GJ; Pieters R; Rottier MM; Veerman AJ
Leuk Res; 2008 Sep; 32(9):1417-23. PubMed ID: 18395253
[TBL] [Abstract][Full Text] [Related]
11. Adipocytes as immune cells: differential expression of TWEAK, BAFF, and APRIL and their receptors (Fn14, BAFF-R, TACI, and BCMA) at different stages of normal and pathological adipose tissue development.
Alexaki VI; Notas G; Pelekanou V; Kampa M; Valkanou M; Theodoropoulos P; Stathopoulos EN; Tsapis A; Castanas E
J Immunol; 2009 Nov; 183(9):5948-56. PubMed ID: 19828625
[TBL] [Abstract][Full Text] [Related]
12. "APRIL hath put a spring of youth in everything": Relevance of APRIL for survival.
Kimberley FC; Hahne M; Medema JP
J Cell Physiol; 2009 Jan; 218(1):1-8. PubMed ID: 18726990
[TBL] [Abstract][Full Text] [Related]
13. Ligand-induced Flt3-downregulation modulates cell death associated proteins and enhances chemosensitivity to idarubicin in THP-1 acute myeloid leukemia cells.
Oveland E; Gjertsen BT; Wergeland L; Selheim F; Fladmark KE; Hovland R
Leuk Res; 2009 Feb; 33(2):276-87. PubMed ID: 18691757
[TBL] [Abstract][Full Text] [Related]
14. Platelet functions and clinical effects in acute myelogenous leukemia.
Foss B; Bruserud O
Thromb Haemost; 2008 Jan; 99(1):27-37. PubMed ID: 18217131
[TBL] [Abstract][Full Text] [Related]
15. Triptolide cooperates with chemotherapy to induce apoptosis in acute myeloid leukemia cells.
Pigneux A; Mahon FX; Uhalde M; Jeanneteau M; Lacombe F; Milpied N; Reiffers J; Belloc F
Exp Hematol; 2008 Dec; 36(12):1648-59. PubMed ID: 18922616
[TBL] [Abstract][Full Text] [Related]
16. Nuclear factor-kappaB as a potential therapeutic target for the novel cytotoxic agent LC-1 in acute myeloid leukaemia.
Jenkins C; Hewamana S; Gilkes A; Neelakantan S; Crooks P; Mills K; Pepper C; Burnett A
Br J Haematol; 2008 Dec; 143(5):661-71. PubMed ID: 19036014
[TBL] [Abstract][Full Text] [Related]
17. Ex vivo detection of primary leukemia cells resistant to granule cytotoxin-induced cell death: a rapid isolation method to study granzyme-B-mediated cell death.
Grüllich C; Friske V; Finke J
Ann Hematol; 2008 Sep; 87(9):701-8. PubMed ID: 18437383
[TBL] [Abstract][Full Text] [Related]
18. Expression and purification of APRIL by auto-induction.
Yu S; Wang Y; Liu Y; Mo W; Song H; Yu M
Protein Expr Purif; 2009 Nov; 68(1):49-53. PubMed ID: 19545632
[TBL] [Abstract][Full Text] [Related]
19. New molecular concepts and targets in acute myeloid leukemia.
Buzzai M; Licht JD
Curr Opin Hematol; 2008 Mar; 15(2):82-7. PubMed ID: 18300752
[TBL] [Abstract][Full Text] [Related]
20. APRIL facilitates viral-induced erythroleukemia but is dispensable for T cell immunity and lymphomagenesis.
Hardenberg G; Fernandez L; Hendriks J; Chebli K; Jacquet C; Sitbon M; Hahne M; Medema JP
J Leukoc Biol; 2008 Aug; 84(2):380-8. PubMed ID: 18483203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
